Wall Street analysts expect Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) to announce ($0.68) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Madrigal Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.71) and the highest estimate coming in at ($0.65). Madrigal Pharmaceuticals reported earnings per share of ($0.67) during the same quarter last year, which indicates a negative year-over-year growth rate of 1.5%. The company is scheduled to report its next earnings report on Monday, April 2nd.
According to Zacks, analysts expect that Madrigal Pharmaceuticals will report full year earnings of ($2.57) per share for the current year, with EPS estimates ranging from ($2.59) to ($2.54). For the next financial year, analysts expect that the firm will report earnings of ($3.24) per share, with EPS estimates ranging from ($3.49) to ($2.98). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Madrigal Pharmaceuticals.
Several research firms recently weighed in on MDGL. Evercore ISI restated an “outperform” rating and issued a $175.00 price target (up previously from $140.00) on shares of Madrigal Pharmaceuticals in a research note on Thursday, February 8th. HC Wainwright upped their price target on Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, December 6th. JMP Securities upped their price target on Madrigal Pharmaceuticals from $63.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 6th. Roth Capital set a $82.00 target price on Madrigal Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, November 30th. Finally, Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $154.20.
Institutional investors and hedge funds have recently modified their holdings of the business. Metropolitan Life Insurance Co. NY purchased a new stake in Madrigal Pharmaceuticals during the 4th quarter valued at $133,000. Covington Capital Management purchased a new stake in Madrigal Pharmaceuticals during the 4th quarter valued at $184,000. MetLife Investment Advisors LLC purchased a new stake in Madrigal Pharmaceuticals during the 4th quarter valued at $194,000. SG Americas Securities LLC purchased a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at $100,000. Finally, Caxton Corp purchased a new stake in Madrigal Pharmaceuticals during the 4th quarter valued at $222,000. Institutional investors and hedge funds own 21.71% of the company’s stock.
Shares of Madrigal Pharmaceuticals (NASDAQ MDGL) opened at $135.11 on Thursday. The firm has a market capitalization of $1,891.81, a P/E ratio of -53.19 and a beta of 1.19. Madrigal Pharmaceuticals has a 52 week low of $13.09 and a 52 week high of $154.75.
TRADEMARK VIOLATION WARNING: This story was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://ledgergazette.com/2018/02/18/1219419.html.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.